A Defining Year for AI in Healthcare and for Our Work

As 2025 comes to a close, it is clear that this has been a pivotal year for artificial intelligence in healthcare. Across drug development, digital health, and patient-centered design, AI has moved from theoretical promise to real-world application. As that shift accelerated, the work happening across The Moxie Health Group and Dr. Ferrer BioPharma gained increasing visibility on both national and international stages.

That momentum was reflected when PharmTech included Dr. Ferrer’s interview in its 2025 recap of notable conversations on AI. The feature highlighted how real-world data, paired with intelligent systems, can be transformed into actionable insights throughout the drug development lifecycle — reinforcing the growing role AI plays in shaping more responsive, efficient, and patient-focused healthcare solutions.

Dr. Ferrer delivers a talk at CPHI Europe 2025.

You can read the full PharmTech interview here. We also published a breakdown on the The Moxie Health Group blog highlighting key takeaways from the conversation.

From South Florida to the Global Stage at MEDICA

Earlier this year, that same innovation was showcased internationally at MEDICA, the world’s largest medical trade fair, held annually in Düsseldorf, Germany.

Dr. Ferrer BioPharma was named a finalist in the Start-up Competition in the Health Apps category for MoxieLink, earning recognition as one of the Top 15 Medical Start-ups of the Year. Selected from more than 230 submissions worldwide, the Hallandale Beach–based biotech company was recognized for its HIPAA-compliant digital platform that unites patient data and uses AI to streamline provider workflows, reduce avoidable hospital readmissions, and improve patient outcomes.

The Top 15 Medical Start-ups at MEDICA 2025.

As part of the competition, Dr. Ferrer BioPharma presented MoxieLink during the MEDICA Start-up Competition Pitch and Award Ceremony and exhibited throughout the four-day conference alongside thousands of healthcare leaders, researchers, and innovators from nearly 70 countries. The recognition positioned the platform within a global conversation around the future of digital health, artificial intelligence, and personalized care.

Closing the Year with Industry Recognition

That international recognition now carries through to the end of the year. Dr. Ferrer BioPharma has been named a finalist for the Pharmapack Awards, in a category recognizing present achievement and future potential.

The Pharmapack Awards honor solutions designed to improve patient and caregiver safety, experience, and adherence, while also spotlighting innovations poised to shape the future of pharmaceutical delivery. This year’s finalists include global leaders such as Abbott Healthcare, Haleon, Aptar Pharma, Ypsomed — and Dr. Ferrer BioPharma, recognized for PrecisaDose, its patient-centered dosing solution.

Winners will be announced in January.

A Year That Points to What’s Next

Taken together, these moments tell a broader story. As AI continues to reshape healthcare, 2025 has marked a period of validation, growth, and visibility for organizations building thoughtful, patient-first technology. From global innovation forums to industry-recognized conversations on AI, our work has been part of that transformation.

As we look ahead to the new year, the excitement isn’t just about recognition — it’s about what comes next. If this year showed what’s possible when AI meets purpose-driven healthcare, the year ahead promises even more.